Related Experiment Video
Updated: Sep 9, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma
Akihiro Miyashita1,2, Taichi Murao3,2, Yuji Shimura2,4
1Department of Internal Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, USA.
Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents used to treat various types of cancer by enhancing T-cell-mediated antitumor activity. These agents have distinct adverse events, known as immune-related adverse events, which can affect multiple organ systems and typically occur within a year after initiating ICI therapy. Another concern regarding ICI therapy is the potential development of T-cell lymphomas due to prolonged activation of T-cell activity. We report the case of a 56-year-old female who was treated with nivolumab for metastatic melanoma for over seven years and subsequently developed concurrent angioimmunoblastic T-cell lymphoma and ICI-related cholangitis. This case highlights the importance of careful monitoring for the emergence of late-onset T-cell lymphoma in patients undergoing long-term ICI therapy.
Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents used to treat various types of cancer by enhancing T-cell-mediated antitumor activity. These agents have distinct adverse events, known as immune-related adverse events, which can affect multiple organ systems and typically occur within a year after initiating ICI therapy. Another concern regarding ICI therapy is the potential development of T-cell lymphomas due to prolonged activation of T-cell activity. We report the case of a 56-year-old female who was treated with nivolumab for metastatic melanoma for over seven years and subsequently developed concurrent angioimmunoblastic T-cell lymphoma and ICI-related cholangitis. This case highlights the importance of careful monitoring for the emergence of late-onset T-cell lymphoma in patients undergoing long-term ICI therapy.
